Evidence map›Paper›PMID 29793891›Full record

ArticleVaccine2018

Sustained impact of rotavirus vaccine on rotavirus hospitalisations in Lusaka, Zambia, 2009-2016.

E M Mpabalwani, J C Simwaka, J M Mwenda, B Matapo, U D Parashar, J E Tate

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Impact of Rotavirus Vaccine Introduction in Children Less Than 2 Years of Age Presenting for Medical Care With Diarrhea in Rural Matlab, Bangladesh.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

E M MpabalwaniUniversity Teaching Hospital, Department of Paediatrics and Child Health, Lusaka, Zambia. Electronic address: evansmwila@gmail.com.
J C SimwakaUniversity Teaching Hospital, Virology Laboratory, Lusaka, Zambia.
J M MwendaWorld Health Organisation, Regional Office for Africa (WHO/AFRO), Brazzaville, People's Republic of Congo.
B MatapoWHO Country Office, Lusaka, Zambia.
U D ParasharCentres for Disease Control and Prevention, Atlanta, GA, USA.
J E TateCentres for Disease Control and Prevention, Atlanta, GA, USA.
University Teaching Hospital · ZMWorld Health Organization Regional Office for Africa · CGWorld Health Organization - Zambia · ZM

Funding

Intramural CDC HHS CC999999World Health Organization 001
6 · The paper itself

Abstract

backgroundMonovalent rotavirus vaccine (RV1) was introduced in Lusaka in February 2012 and rolled out countrywide in November 2013 in the routine Expanded Programme on Immunisation and administered at 6 and 10 weeks with no catch up dose. Reported here is the monitoring of rotavirus acute gastroenteritis hospitalisations at the University Teaching Hospital, Lusaka, Zambia as part of efforts to document the impact of rotavirus vaccine.

methodsChildren <5 years hospitalised for acute gastroenteritis (AGE) from January 2009 to December 2016 were recruited into the rotavirus disease burden active surveillance and had their stools tested for rotavirus by enzyme immunoassay. We compared rotavirus-associated AGE hospitalisations of the pre-vaccine era (2009-2011) with the post-rotavirus vaccine introduction period (2013-2016).

resultsWith the increase in RV1 coverage in Lusaka, rotavirus AGE declined significantly from 40% of diarrhoea hospitalisation in the pre-vaccine era to 29% of diarrhoea hospitalisation in the post-vaccine era (p < 0.001) in children <5 years. After a decreasing trend in rotavirus positivity from 2013 to 2015, positivity increased to 37% in 2016. However, the post-vaccine years (2012-2016) saw substantial decline in the number tested (median decline: 34% (range: 20-43%)) and the number of positive results (median decline: 52% (range: 30-65%).

conclusionA sustained and significant decline in rotavirus AGE hospitalisations was observed in children <5 years since the introduction of RV1 in Lusaka, Zambia. Despite an increase in rotavirus positivity in 2016, the total number of children enrolled and the number of rotavirus positive children remained below baseline. The reason for the increase in rotavirus positivity in 2016 is unknown but could be due to an accumulation of susceptible children and the shifting of disease to children of older age groups. This finding underscores the need for continued monitoring of rotavirus vaccine impact.

Indexed as

Immunization ProgramsAcute DiseaseChild, PreschoolDiarrheaFecesGastroenteritisHospitalizationHumansImmunoassayInfantRotavirusRotavirus InfectionsRotavirus VaccinesVaccination CoverageVaccines, AttenuatedZambiaRIX4414 vaccineRotavirus VaccinesVaccines, AttenuatedAcute gastroenteritisHospitalisationRotavirus vaccineSustained impact

Identifiers

PMID29793891
PMCPMC11973831
OpenAlexW2804351879

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.